(Q37256709)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18759551%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

review article

1 reference

title

Role of glutamate in schizophrenia: integrating excitatory avenues of research (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18759551%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18759551%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

author name string

Kimberly H Wood

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18759551%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

James Meador-Woodruff

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18759551%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

publication date

1 September 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18759551%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

13 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18759551%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18759551%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18759551%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

page(s)

1389-1406

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18759551%20AND%20SRC:MED&resulttype=core&format=json

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

13 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Some neurophysiological aspects of serotonin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Serotonin receptors: their key role in drugs to treat schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Cognitive improvement in schizophrenia with novel antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Recent advances in the phencyclidine model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Glutamate and schizophrenia: beyond the dopamine hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Schizophrenia as a disorder of neuroplasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Molecular abnormalities of the glutamate synapse in the thalamus in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Glutamate receptors of the kainate type and synaptic transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

The TINS/TiPS Lecture. The molecular biology of mammalian glutamate receptor channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Pharmacology and functions of metabotropic glutamate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Dopamine receptors and the dopamine hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

A systems model of altered consciousness: integrating natural and drug-induced psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Ketamine displaces the novel NMDA receptor SPET probe [(123)I]CNS-1261 in humans in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Modulation of memory fields by dopamine D1 receptors in prefrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

The 5-HT receptor antagonist M100,907 prevents extracellular glutamate rising in response to NMDA receptor blockade in the mPFC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Heritability estimates for psychotic disorders: the Maudsley twin psychosis series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

The genetic deconstruction of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Endophenotypes in the genetic analyses of mental disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Alternative splicing of human metabotropic glutamate receptor 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Effect of metabotropic glutamate receptor 3 genotype on N-acetylaspartate measures in the dorsolateral prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Altered cortical glutamate neurotransmission in schizophrenia: evidence from morphological studies of pyramidal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Association between the neuregulin 1 gene and schizophrenia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Genetic studies of neuropsychiatric disorders in Costa Rica: a model for the use of isolated populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Identification of a high-risk haplotype for the dystrobrevin binding protein 1 (DTNBP1) gene in the Irish study of high-density schizophrenia families

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Strong evidence for association between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia in 488 parent-offspring trios from Bulgaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Is the dysbindin gene (DTNBP1) a susceptibility gene for schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Dysbindin genotype and negative symptoms in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Genetic variation in DTNBP1 influences general cognitive ability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Association of schizophrenia with DTNBP1 but not with DAO, DAOA, NRG1 and RGS4 nor their genetic interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Effect of systemic administration of D-serine on the levels of D- and L-serine in several brain areas and periphery of rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

D-serine added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Metabotropic glutamate receptor agonists for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Glutamate agonists for schizophrenia stimulate dopamine D2High receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Dopamine partial agonist actions of the glutamate receptor agonists LY 354,740 and LY 379,268.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Blood-brain barrier transport of non-viral gene and RNAi therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Genetic regulation of glutamate receptor ion channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

AMPA-receptor GluR1 subunits are involved in the control over behavior by cocaine-paired cues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Positive association of the AMPA receptor subunit GluR4 gene (GRIA4) haplotype with schizophrenia: linkage disequilibrium mapping using SNPs evenly distributed across the gene region

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

No genetic association between polymorphisms in the AMPA receptor subunit GluR4 gene (GRIA4) and schizophrenia in the Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Association between the ionotropic glutamate receptor kainate 3 (GRIK3) ser310ala polymorphism and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

No association between the ionotropic glutamate receptor kainate 3 gene ser310ala polymorphism and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Association study of polymorphisms in the GluR7, KA1 and KA2 kainate receptor genes (GRIK3, GRIK4, GRIK5) with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Are some genetic risk factors common to schizophrenia, bipolar disorder and depression? Evidence from DISC1, GRIK4 and NRG1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

No genetic association between polymorphisms in the kainate-type glutamate receptor gene, GRIK4, and schizophrenia in the Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Systematic mutation analysis of the human glutamate receptor, ionotropic, N-methyl-D-aspartate 1 gene(GRIN1) in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Possible association between genetic variants at the GRIN1 gene and schizophrenia with lifetime history of depressive symptoms in a German sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

N‐methyl‐d‐aspartate receptor NR1 subunit gene (GRIN1) in schizophrenia: TDT and case‐control analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Determination of the genomic structure and mutation screening in schizophrenic individuals for five subunits of the N-methyl-D-aspartate glutamate receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Significant association between the genetic variations in the 5' end of the N-methyl-D-aspartate receptor subunit gene GRIN1 and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

A family-based association study and gene expression analyses of netrin-G1 and -G2 genes in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

A case-control association study between the GRID1 gene and schizophrenia in the Chinese Northern Han population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Vesicular glutamate transporter 2 is required for central respiratory rhythm generation but not for locomotor central pattern generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Association study of polymorphisms in the excitatory amino acid transporter 2 gene (SLC1A2) with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Vesicular glutamate transporter 1 is required for photoreceptor synaptic signaling but not for intrinsic visual functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Glutamate transporters GLAST and EAAT4 regulate postischemic Purkinje cell death: an in vivo study using a cardiac arrest model in mice lacking GLAST or EAAT4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Structure and polymorphisms of the human metabotropic glutamate receptor type 2 gene (GRM2): analysis of association with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Enhanced cocaine responsiveness and impaired motor coordination in metabotropic glutamate receptor subtype 2 knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

No association between the metabotropic glutamate receptor type 3 gene (GRM3) and schizophrenia in a Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

No evidence for association between polymorphisms in GRM3 and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Large-scale case-control study of a functional polymorphism in the glutamate receptor, metabotropic 3 gene in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Mutation screening of the metabotropic glutamate receptor mGluR4 (GRM4) gene in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Mice lacking metabotropic glutamate receptor 4 do not show the motor stimulatory effect of ethanol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Polymorphisms in the genes for mGluR types 7 and 8: association studies with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Lack of the metabotropic glutamate receptor subtype 7 selectively impairs short-term working memory but not long-term memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Positive associations of polymorphisms in the metabotropic glutamate receptor type 8 gene (GRM8) with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Increased measures of anxiety and weight gain in mice lacking the group III metabotropic glutamate receptor mGluR8

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

The dysbindin gene (DTNBP1) and schizophrenia: no support for an association in the Korean population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Identification in 2 independent samples of a novel schizophrenia risk haplotype of the dystrobrevin binding protein gene (DTNBP1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Association between the DTNBP1 gene and intelligence: a case-control study in young patients with schizophrenia and related disorders and unaffected siblings

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

High dopamine turnover in the brains of Sandy mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Neuregulin 1 and susceptibility to schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Genes for schizophrenia? Recent findings and their pathophysiological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Association study of neuregulin 1 gene with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

No evidence for linkage or association of neuregulin-1 (NRG1) with disease in the Irish study of high-density schizophrenia families (ISHDSF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

A case control and family based association study of the neuregulin1 gene and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

A family-based study of the association between the G72/G30 genes and schizophrenia in the Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Association of Neuregulin 1 with schizophrenia and bipolar disorder in a second cohort from the Scottish population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Support for neuregulin 1 as a susceptibility gene for bipolar disorder and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Polymorphisms in the 13q33.2 gene G72/G30 are associated with childhood-onset schizophrenia and psychosis not otherwise specified

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Is the G72/G30 locus associated with schizophrenia? single nucleotide polymorphisms, haplotypes, and gene expression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Glutamate signaling to Ras-MAPK in striatal neurons: mechanisms for inducible gene expression and plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Association analyses of the DAOA/G30 and D-amino-acid oxidase genes in schizophrenia: further evidence for a role in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Further evidence for the association between G72/G30 genes and schizophrenia in two ethnically distinct populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

No association of G72 and D-amino acid oxidase genes with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

The G72/G30 gene complex and cognitive abnormalities in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Family-based association study between G72/G30 genetic polymorphism and schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Association of G72/G30 polymorphisms with early-onset and male schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Association of DAOA polymorphisms with schizophrenia and clinical symptoms or therapeutic effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

G72/G30 genes and schizophrenia: a systematic meta-analysis of association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

D-amino acid oxidase (DAO) genotype and mood symptomatology in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Identification of single-nucleotide polymorphisms in the human N-methyl-D-aspartate receptor subunit NR2D gene, GRIN2D, and association study with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Association study of polymorphisms in the GluR5 kainate receptor gene (GRIK1) with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Association study between the NMDA receptor 2B subunit gene (GRIN2B) and schizophrenia: a HuGE review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Future therapies for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

Findings in an independent sample support an association between bipolar affective disorder and the G72/G30 locus on chromosome 13q33

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

No evidence for association between a non-synonymous polymorphism in the gene encoding human metabotropic glutamate receptor 7 and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389

The role of DTNBP1, NRG1, and AKT1 in the genetics of schizophrenia in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1389